Src Inhibitors

The Src family of kinases (SFKs) consists of non-receptor tyrosine kinases, with c-Src being the prototypical member. Src is a key integrator of signals from a wide variety of cell surface receptors, including receptor tyrosine kinases (RTKs), G-protein-coupled receptors (GPCRs), and integrins. Structurally, Src contains a myristoylation site for membrane localization, followed by SH3, SH2, and catalytic kinase domains. Its activity is tightly regulated by the phosphorylation of two key tyrosine residues: autophosphorylation of Y416 activates the enzyme, while phosphorylation of Y527 by C-terminal Src kinase (Csk) promotes an autoinhibited, closed conformation. When activated, Src modulates pathways involved in cell proliferation (Ras/MAPK), survival (PI3K/Akt), and, most notably, cytoskeletal remodeling and motility through its interactions with focal adhesion kinase (FAK) and paxillin. Consequently, Src is frequently overexpressed or hyperactivated in many solid tumors, where it drives epithelial-mesenchymal transition (EMT), invasion, and metastasis.

Src inhibitors are primarily small-molecule, ATP-competitive compounds. They are often classified into dual-target inhibitors and more selective Src inhibitors. Dasatinib is perhaps the most well-known, originally developed as a dual Bcr-Abl and Src inhibitor. It is FDA-approved for the treatment of Philadelphia chromosome-positive (Ph+) leukemias, where its ability to inhibit Src provides an additional mechanism to overcome certain Bcr-Abl mutations. Other dual inhibitors include bosutinib (Src/Abl) and saracatinib (AZD0530), which targets both Src and Abl but has been primarily studied in solid tumors. More selective Src inhibitors, such as tirbanibulin, have also been developed; tirbanibulin was recently approved as a topical treatment for actinic keratosis, acting by inhibiting Src signaling and tubulin polymerization.

Despite the clear role of Src in tumor progression, the clinical success of Src inhibitors as monotherapy in solid tumors has been limited. This is largely because Src often functions as a node rather than a primary driver mutation, meaning that cells can frequently bypass Src inhibition through alternative signaling pathways. Current research is therefore heavily focused on combination strategies. For example, combining Src inhibitors with EGFR or HER2 inhibitors can sensitize resistant tumors to these therapies. Additionally, Src's role in bone metabolism—specifically its necessity for osteoclast function—has led to investigations into its use for treating bone metastases and osteoporosis. Challenges include managing toxicities such as pleural effusion (associated with dasatinib) and identifying the specific patient populations most likely to benefit from Src-directed therapy.

Emerging research is also exploring the role of Src in the tumor microenvironment, particularly its influence on immune cell infiltration and the activation of cancer-associated fibroblasts. This includes investigating how Src signaling in the stroma contributes to the physical barriers that prevent drug delivery and immune cell access to the tumor core.